NO311807B1 - HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV - Google Patents

HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV Download PDF

Info

Publication number: NO311807B1
Authority: NO; Norway
Prior art keywords: xaa; seq; leu; gly; ala
Prior art date: 1999-03-04

Application number

NO19991078A

Other languages

English (en)

Norwegian (no)

Other versions

NO991078D0 (no

NO991078L (no

Inventor

Birger Soerensen

Original Assignee

Bionor Immuno As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-04

Filing date

1999-03-04

Publication date

2002-01-28

1999-03-04 Application filed by Bionor Immuno As filed Critical Bionor Immuno As

1999-03-04 Priority to NO19991078A priority Critical patent/NO311807B1/no

1999-03-04 Publication of NO991078D0 publication Critical patent/NO991078D0/no

2000-03-02 Priority to BR0008741-6A priority patent/BR0008741A/pt

2000-03-02 Priority to AT00911492T priority patent/ATE397014T1/de

2000-03-02 Priority to CNA2008100921326A priority patent/CN101328210A/zh

2000-03-02 Priority to JP2000602264A priority patent/JP2002541069A/ja

2000-03-02 Priority to CNB008057354A priority patent/CN100387617C/zh

2000-03-02 Priority to CNA2008100921330A priority patent/CN101328208A/zh

2000-03-02 Priority to NZ525751A priority patent/NZ525751A/en

2000-03-02 Priority to IDW00200102137A priority patent/ID30497A/id

2000-03-02 Priority to CA002363947A priority patent/CA2363947C/fr

2000-03-02 Priority to PT00911492T priority patent/PT1159298E/pt

2000-03-02 Priority to HK02106292.0A priority patent/HK1044778B/zh

2000-03-02 Priority to NZ514619A priority patent/NZ514619A/en

2000-03-02 Priority to ES00911492T priority patent/ES2307496T4/es

2000-03-02 Priority to HU0200265A priority patent/HU229282B1/hu

2000-03-02 Priority to SK1240-2001A priority patent/SK287382B6/sk

2000-03-02 Priority to PCT/NO2000/000075 priority patent/WO2000052040A1/fr

2000-03-02 Priority to DE60039036T priority patent/DE60039036D1/de

2000-03-02 Priority to EP00911492A priority patent/EP1159298B1/fr

2000-03-02 Priority to CZ20013195A priority patent/CZ300505B6/cs

2000-03-02 Priority to US09/674,674 priority patent/US6706859B1/en

2000-03-02 Priority to AU33358/00A priority patent/AU771827B2/en

2000-03-02 Priority to CNA2008100921311A priority patent/CN101328209A/zh

2000-03-02 Priority to EA200100943A priority patent/EA004802B9/ru

2000-03-02 Priority to NZ525752A priority patent/NZ525752A/en

2000-03-02 Priority to NZ525753A priority patent/NZ525753A/en

2000-03-02 Priority to DK00911492T priority patent/DK1159298T3/da

2000-09-05 Publication of NO991078L publication Critical patent/NO991078L/no

2001-08-27 Priority to ZA200107072A priority patent/ZA200107072B/xx

2002-01-28 Publication of NO311807B1 publication Critical patent/NO311807B1/no

2003-09-11 Priority to US10/659,324 priority patent/US7311915B2/en

2007-10-01 Priority to US11/865,106 priority patent/US7709003B2/en

2007-10-01 Priority to US11/865,109 priority patent/US7709004B2/en

2008-08-28 Priority to CY20081100922T priority patent/CY1108299T1/el

2010-12-09 Priority to JP2010275025A priority patent/JP5313998B2/ja

2012-10-31 Priority to JP2012240131A priority patent/JP5695012B2/ja

2012-10-31 Priority to JP2012239940A priority patent/JP5695010B2/ja

2013-12-02 Priority to JP2013249096A priority patent/JP5814331B2/ja

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 114
102000004196 processed proteins & peptides Human genes 0.000 title claims description 49
239000000427 antigen Substances 0.000 title claims description 33
108091007433 antigens Proteins 0.000 title claims description 33
102000036639 antigens Human genes 0.000 title claims description 33
229960005486 vaccine Drugs 0.000 title claims description 33
238000002360 preparation method Methods 0.000 title claims description 28
238000000034 method Methods 0.000 title claims description 8
238000003018 immunoassay Methods 0.000 title claims description 7
150000001413 amino acids Chemical group 0.000 claims description 45
241000725303 Human immunodeficiency virus Species 0.000 claims description 20
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 20
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 claims description 19
101710205625 Capsid protein p24 Proteins 0.000 claims description 19
101710177166 Phosphoprotein Proteins 0.000 claims description 19
101710149279 Small delta antigen Proteins 0.000 claims description 19
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 claims description 19
239000002671 adjuvant Substances 0.000 claims description 19
102000004169 proteins and genes Human genes 0.000 claims description 15
108090000623 proteins and genes Proteins 0.000 claims description 15
150000001408 amides Chemical class 0.000 claims description 14
238000001514 detection method Methods 0.000 claims description 7
239000003102 growth factor Substances 0.000 claims description 6
239000000470 constituent Substances 0.000 claims description 5
230000003308 immunostimulating effect Effects 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
239000010839 body fluid Substances 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
238000012986 modification Methods 0.000 claims description 3
230000004048 modification Effects 0.000 claims description 3
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 claims description 2
WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 claims description 2
FKVNLUZHSFCNGY-RVMXOQNASA-N Pro-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 FKVNLUZHSFCNGY-RVMXOQNASA-N 0.000 claims description 2
SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 claims description 2
IWAVRIPRTCJAQO-HSHDSVGOSA-N Thr-Pro-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IWAVRIPRTCJAQO-HSHDSVGOSA-N 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
239000007864 aqueous solution Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 32
238000004128 high performance liquid chromatography Methods 0.000 description 25
208000031886 HIV Infections Diseases 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 19
238000003786 synthesis reaction Methods 0.000 description 19
238000004458 analytical method Methods 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
239000000243 solution Substances 0.000 description 14
238000004989 laser desorption mass spectroscopy Methods 0.000 description 13
238000004949 mass spectrometry Methods 0.000 description 13
208000030507 AIDS Diseases 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
239000007858 starting material Substances 0.000 description 12
235000018102 proteins Nutrition 0.000 description 11
238000011161 development Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
239000002245 particle Substances 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000000969 carrier Substances 0.000 description 7
230000028993 immune response Effects 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
210000000987 immune system Anatomy 0.000 description 6
239000006249 magnetic particle Substances 0.000 description 6
208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 5
239000012458 free base Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000037396 body weight Effects 0.000 description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
238000010183 spectrum analysis Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
229940021993 prophylactic vaccine Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
229940021747 therapeutic vaccine Drugs 0.000 description 3
229940125575 vaccine candidate Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010040914 Skin reaction Diseases 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000035483 skin reaction Effects 0.000 description 2
231100000430 skin reaction Toxicity 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
OIOAKXPMBIZAHL-LURJTMIESA-N (2s)-2-azaniumyl-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(O)=O OIOAKXPMBIZAHL-LURJTMIESA-N 0.000 description 1
ANAZDOWEOOFEET-UHFFFAOYSA-N (4-hydroxyphenyl) [4-(3-oxo-1h-2-benzofuran-1-yl)phenyl] hydrogen phosphate Chemical compound C1=CC(O)=CC=C1OP(O)(=O)OC1=CC=C(C2C3=CC=CC=C3C(=O)O2)C=C1 ANAZDOWEOOFEET-UHFFFAOYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229940033330 HIV vaccine Drugs 0.000 description 1
108700020403 Human Immunodeficiency Virus Type 1 p24 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229940037003 alum Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006229 carbon black Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
101150030339 env gene Proteins 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011850 initial investigation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000048 toxicity data Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
AIDS & HIV (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

NO19991078A 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV NO311807B1 (no)

Priority Applications (36)

Application Number	Priority Date	Filing Date	Title
NO19991078A NO311807B1 (no)	1999-03-04	1999-03-04	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
DK00911492T DK1159298T3 (da)	1999-03-04	2000-03-02	HIV-peptider, antigener og vaccinekompositioner
EP00911492A EP1159298B1 (fr)	1999-03-04	2000-03-02	Peptides, antigenes du vih, et compositions de vaccins afferentes
CZ20013195A CZ300505B6 (cs)	1999-03-04	2000-03-02	Vakcinacní prípravek
CNA2008100921326A CN101328210A (zh)	1999-03-04	2000-03-02	Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
JP2000602264A JP2002541069A (ja)	1999-03-04	2000-03-02	Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
CNB008057354A CN100387617C (zh)	1999-03-04	2000-03-02	Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法
AU33358/00A AU771827B2 (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
NZ525751A NZ525751A (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
IDW00200102137A ID30497A (id)	1999-03-04	2000-03-02	Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
CA002363947A CA2363947C (fr)	1999-03-04	2000-03-02	Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
PT00911492T PT1159298E (pt)	1999-03-04	2000-03-02	Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
HK02106292.0A HK1044778B (zh)	1999-03-04	2000-03-02	Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
NZ514619A NZ514619A (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ES00911492T ES2307496T4 (es)	1999-03-04	2000-03-02	Composiciones de vacuna, antígenos y péptidos de VIH
HU0200265A HU229282B1 (en)	1999-03-04	2000-03-02	Hiv vaccine compositions
SK1240-2001A SK287382B6 (sk)	1999-03-04	2000-03-02	Očkovacia kompozícia
PCT/NO2000/000075 WO2000052040A1 (fr)	1999-03-04	2000-03-02	Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
DE60039036T DE60039036D1 (de)	1999-03-04	2000-03-02	Hiv-peptide, antigene und impfstoffzusammensetzungen
BR0008741-6A BR0008741A (pt)	1999-03-04	2000-03-02	Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv
US09/674,674 US6706859B1 (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AT00911492T ATE397014T1 (de)	1999-03-04	2000-03-02	Hiv-peptide, antigene und impfstoffzusammensetzungen
CNA2008100921330A CN101328208A (zh)	1999-03-04	2000-03-02	Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
CNA2008100921311A CN101328209A (zh)	1999-03-04	2000-03-02	Hiv肽，抗原，疫苗组合物，检测hiv所诱导的抗体的免疫测定试剂盒及方法
EA200100943A EA004802B9 (ru)	1999-03-04	2000-03-02	МОДИФИЦИРОВАННЫЕ ВИЧ-ПЕПТИДЫ НА ОСНОВЕ БЕЛКА gag p24, АНТИГЕНЫ, ВАКЦИННЫЕ КОМПОЗИЦИИ, НАБОР ДЛЯ ИММУНОАНАЛИЗА И СПОСОБ ОПРЕДЕЛЕНИЯ ВИЧ-ИНДУЦИРОВАННЫХ АНТИТЕЛ
NZ525752A NZ525752A (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
NZ525753A NZ525753A (en)	1999-03-04	2000-03-02	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ZA200107072A ZA200107072B (en)	1999-03-04	2001-08-27	HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
US10/659,324 US7311915B2 (en)	1999-03-04	2003-09-11	Method of producing an HIV-1 immune response
US11/865,106 US7709003B2 (en)	1999-03-04	2007-10-01	Method of producing an HIV-1 immune response
US11/865,109 US7709004B2 (en)	1999-03-04	2007-10-01	Method of producing an HIV-1 immune response
CY20081100922T CY1108299T1 (el)	1999-03-04	2008-08-28	Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου
JP2010275025A JP5313998B2 (ja)	1999-03-04	2010-12-09	Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2012240131A JP5695012B2 (ja)	1999-03-04	2012-10-31	Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2012239940A JP5695010B2 (ja)	1999-03-04	2012-10-31	Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
JP2013249096A JP5814331B2 (ja)	1999-03-04	2013-12-02	Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO19991078A NO311807B1 (no)	1999-03-04	1999-03-04	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Publications (3)

Publication Number	Publication Date
NO991078D0 NO991078D0 (no)	1999-03-04
NO991078L NO991078L (no)	2000-09-05
NO311807B1 true NO311807B1 (no)	2002-01-28

Family

ID=19903050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991078A NO311807B1 (no)	1999-03-04	1999-03-04	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Country Status (23)

Country	Link
US (4)	US6706859B1 (fr)
EP (1)	EP1159298B1 (fr)
JP (5)	JP2002541069A (fr)
CN (4)	CN101328208A (fr)
AT (1)	ATE397014T1 (fr)
AU (1)	AU771827B2 (fr)
BR (1)	BR0008741A (fr)
CA (1)	CA2363947C (fr)
CY (1)	CY1108299T1 (fr)
CZ (1)	CZ300505B6 (fr)
DE (1)	DE60039036D1 (fr)
DK (1)	DK1159298T3 (fr)
EA (1)	EA004802B9 (fr)
ES (1)	ES2307496T4 (fr)
HK (1)	HK1044778B (fr)
HU (1)	HU229282B1 (fr)
ID (1)	ID30497A (fr)
NO (1)	NO311807B1 (fr)
NZ (4)	NZ514619A (fr)
PT (1)	PT1159298E (fr)
SK (1)	SK287382B6 (fr)
WO (1)	WO2000052040A1 (fr)
ZA (1)	ZA200107072B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL150961A0 (en)	2000-02-04	2003-02-12	Univ Duke	Human immunodeficiency virus vaccine
NO314588B1 (no)	2000-09-04	2003-04-14	Bionor Immuno As	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) *	2000-09-04	2003-04-14	Bionor Immuno As	HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
PL2392587T3 (pl)	2006-03-10	2016-08-31	Peptcell Ltd	Sekwencje i kompozycje peptydów
KR101701198B1 (ko)	2008-06-19	2017-02-01	배리에이션 바이오테크놀로지스 아이엔씨.	인플루엔자를 치료하기 위한 조성물 및 방법
CA2803282C (fr)	2009-07-06	2018-05-01	David E. Anderson	Procedes pour preparer des vesicules et formulations produites a partir de ces procedes
CN102482666B (zh)	2009-07-06	2017-02-08	变异生物技术公司	制备囊泡的方法和由其产生的制剂
WO2011119920A2 (fr)	2010-03-25	2011-09-29	Oregon Health & Science University	Glycoprotéines du cmv et vecteurs recombinés
CN103096922B (zh)	2010-07-06	2019-08-06	变异生物技术公司	用于治疗流行性感冒的组合物和方法
CN103282375B (zh) *	2010-12-02	2017-01-11	比奥诺尔免疫有限公司	肽支架设计
BR112013017939B1 (pt)	2011-01-13	2022-11-16	Variation Biotechnologies Inc	Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (fr)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
EP2586461A1 (fr)	2011-10-27	2013-05-01	Christopher L. Parks	Particules virales dérivées d'un virus enveloppé
EP2802353A4 (fr)	2012-01-12	2015-12-02	Variation Biotechnologies Inc	Compositions et méthodes de traitement d'infections virales
CN104244984B (zh)	2012-01-27	2020-03-31	变异生物技术公司	用于治疗剂的方法和组合物
MX2014014683A (es)	2012-06-06	2015-02-24	Bionor Immuno As	Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
CA2875624A1 (fr) *	2012-06-06	2013-12-12	Bionor Immuno As	Vaccin contre le vih
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (fr)	2013-07-19	2015-01-22	Bionor Immuno As	Procédé de vaccination contre le vih
WO2015022401A1 (fr) *	2013-08-14	2015-02-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions d'immunoadjuvants et leurs utilisations
EP2848937A1 (fr)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Trimères de glycoprotéines d'enveloppe du vih -1 soluble
WO2015086738A2 (fr) *	2013-12-11	2015-06-18	Bionor Immuno As	Vaccin contre le vih
AU2015208033B2 (en)	2014-01-27	2019-02-07	Bionor Immuno As	Method for the vaccination against HIV
WO2015110659A1 (fr) *	2014-01-27	2015-07-30	Bionor Immuno As	Méthodes d'immunisation avec un vaccin induisant une réponse immunitaire humorale et avec un vaccin induisant une réponse immunitaire cellulaire
EP3099318A1 (fr)	2014-01-27	2016-12-07	Bionor Immuno AS	Schéma posologique d'un vaccin contre le vih
US10407464B2 (en) *	2014-04-03	2019-09-10	Amgen Inc.	Method for preparing AMG 416
WO2016005508A1 (fr)	2014-07-11	2016-01-14	Bionor Immuno As	Procédé permettant de réduire et/ou de retarder les effets pathologiques du virus de l'immunodéficience humaine i (vih) ou de réduire le risque de développer le syndrome d'immunodéficience acquise (sida)
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US20180140694A1 (en)	2015-05-04	2018-05-24	Bionor Immuno As	Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (fr)	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression du gène gag de HTLV-III
US4925784A (en)	1986-04-04	1990-05-15	Hoffmann-La Roche Inc.	Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en)	1986-12-05	1987-01-14	Hoffmann La Roche	Env/gag polypeptides
IE63455B1 (en)	1987-09-04	1995-04-19	Int Murex Tech Corp	Immunoassay and biological constructs for use therein
US4888290A (en) *	1987-11-06	1989-12-19	Coulter Corporation	Monoclonal antibody specific to HIV antigens
EP0356007A3 (fr) *	1988-07-22	1991-07-03	Medical Research Council	Déterminants antigéniques
KR940000755B1 (ko) *	1990-02-16	1994-01-29	유나이티드 바이오메디칼 인코오포레이티드	Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv)	1990-02-20	1992-11-16	Replico Medical Ab	Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) *	1992-09-14	1994-02-22	The Regents Of The University Of California	Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) *	1993-03-31	1996-09-06	Fernand Narbey Torossian	Complexe immunomodulateur anti SIDA.
WO1994028871A1 (fr) *	1993-06-07	1994-12-22	Endocon, Inc.	Immunite a mediation cellulaire stimulee par implant
AU685521B2 (en) *	1993-10-19	1998-01-22	Ajinomoto Co., Inc.	Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
FR2731013B1 (fr) *	1995-02-27	1997-05-16	Inst Nat Sante Rech Med	Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
ES2187947T5 (es)	1997-03-10	2014-01-29	Roche Diagnostics Gmbh	Procedimiento para la detección simultánea de antígenos de HIV y anticuerpos de HIV

1999
- 1999-03-04 NO NO19991078A patent/NO311807B1/no not_active IP Right Cessation
2000
- 2000-03-02 WO PCT/NO2000/000075 patent/WO2000052040A1/fr not_active Ceased
- 2000-03-02 HU HU0200265A patent/HU229282B1/hu not_active IP Right Cessation
- 2000-03-02 CZ CZ20013195A patent/CZ300505B6/cs not_active IP Right Cessation
- 2000-03-02 CA CA002363947A patent/CA2363947C/fr not_active Expired - Fee Related
- 2000-03-02 CN CNA2008100921330A patent/CN101328208A/zh active Pending
- 2000-03-02 ID IDW00200102137A patent/ID30497A/id unknown
- 2000-03-02 NZ NZ514619A patent/NZ514619A/en not_active IP Right Cessation
- 2000-03-02 NZ NZ525752A patent/NZ525752A/en not_active IP Right Cessation
- 2000-03-02 ES ES00911492T patent/ES2307496T4/es not_active Expired - Lifetime
- 2000-03-02 CN CNA2008100921311A patent/CN101328209A/zh active Pending
- 2000-03-02 DE DE60039036T patent/DE60039036D1/de not_active Expired - Lifetime
- 2000-03-02 PT PT00911492T patent/PT1159298E/pt unknown
- 2000-03-02 NZ NZ525751A patent/NZ525751A/en not_active IP Right Cessation
- 2000-03-02 HK HK02106292.0A patent/HK1044778B/zh not_active IP Right Cessation
- 2000-03-02 AT AT00911492T patent/ATE397014T1/de active
- 2000-03-02 JP JP2000602264A patent/JP2002541069A/ja active Pending
- 2000-03-02 US US09/674,674 patent/US6706859B1/en not_active Expired - Lifetime
- 2000-03-02 AU AU33358/00A patent/AU771827B2/en not_active Ceased
- 2000-03-02 EP EP00911492A patent/EP1159298B1/fr not_active Expired - Lifetime
- 2000-03-02 SK SK1240-2001A patent/SK287382B6/sk not_active IP Right Cessation
- 2000-03-02 DK DK00911492T patent/DK1159298T3/da active
- 2000-03-02 NZ NZ525753A patent/NZ525753A/en not_active IP Right Cessation
- 2000-03-02 EA EA200100943A patent/EA004802B9/ru not_active IP Right Cessation
- 2000-03-02 CN CNA2008100921326A patent/CN101328210A/zh active Pending
- 2000-03-02 CN CNB008057354A patent/CN100387617C/zh not_active Expired - Fee Related
- 2000-03-02 BR BR0008741-6A patent/BR0008741A/pt not_active IP Right Cessation
2001
- 2001-08-27 ZA ZA200107072A patent/ZA200107072B/xx unknown
2003
- 2003-09-11 US US10/659,324 patent/US7311915B2/en not_active Expired - Fee Related
2007
- 2007-10-01 US US11/865,109 patent/US7709004B2/en not_active Expired - Fee Related
- 2007-10-01 US US11/865,106 patent/US7709003B2/en not_active Expired - Fee Related
2008
- 2008-08-28 CY CY20081100922T patent/CY1108299T1/el unknown
2010
- 2010-12-09 JP JP2010275025A patent/JP5313998B2/ja not_active Expired - Fee Related
2012
- 2012-10-31 JP JP2012239940A patent/JP5695010B2/ja not_active Expired - Fee Related
- 2012-10-31 JP JP2012240131A patent/JP5695012B2/ja not_active Expired - Fee Related
2013
- 2013-12-02 JP JP2013249096A patent/JP5814331B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101328209A (zh)	2008-12-24
DE60039036D1 (de)	2008-07-10
CZ300505B6 (cs)	2009-06-03
WO2000052040A1 (fr)	2000-09-08
EA004802B9 (ru)	2015-03-31
EP1159298B1 (fr)	2008-05-28
NZ525752A (en)	2004-10-29
CN1346367A (zh)	2002-04-24
NZ525751A (en)	2004-10-29
JP5313998B2 (ja)	2013-10-09
US20080107670A1 (en)	2008-05-08
US7709003B2 (en)	2010-05-04
HUP0200265A2 (en)	2002-06-29
JP5814331B2 (ja)	2015-11-17
JP2011074081A (ja)	2011-04-14
AU3335800A (en)	2000-09-21
CA2363947A1 (fr)	2000-09-08
CY1108299T1 (el)	2014-02-12
CN101328210A (zh)	2008-12-24
NZ525753A (en)	2004-10-29
SK12402001A3 (sk)	2002-02-05
CN100387617C (zh)	2008-05-14
SK287382B6 (sk)	2010-08-09
ATE397014T1 (de)	2008-06-15
CA2363947C (fr)	2008-05-20
JP2002541069A (ja)	2002-12-03
JP2013032384A (ja)	2013-02-14
EA004802B1 (ru)	2004-08-26
US20080107669A1 (en)	2008-05-08
US6706859B1 (en)	2004-03-16
CN101328208A (zh)	2008-12-24
HK1044778A1 (en)	2002-11-01
NZ514619A (en)	2003-10-31
ES2307496T3 (es)	2008-12-01
US7709004B2 (en)	2010-05-04
ES2307496T4 (es)	2015-03-06
US20040259797A1 (en)	2004-12-23
DK1159298T3 (da)	2008-08-25
JP5695012B2 (ja)	2015-04-01
PT1159298E (pt)	2008-09-04
JP2013032386A (ja)	2013-02-14
JP2014043468A (ja)	2014-03-13
EA200100943A1 (ru)	2002-02-28
CZ20013195A3 (cs)	2002-02-13
ZA200107072B (en)	2002-11-27
HU229282B1 (en)	2013-10-28
EP1159298A1 (fr)	2001-12-05
HK1044778B (zh)	2009-04-24
NO991078D0 (no)	1999-03-04
BR0008741A (pt)	2002-01-08
AU771827B2 (en)	2004-04-01
US7311915B2 (en)	2007-12-25
ID30497A (id)	2001-12-13
NO991078L (no)	2000-09-05
JP5695010B2 (ja)	2015-04-01

Legal Events

Date	Code	Title	Description
2018-10-22	MM1K	Lapsed by not paying the annual fees